Srini Ramanathan

Background

About Srini Ramanathan

Chief Development Officer at Roivant Sciences.R&D oversight of diligence, intake, and stand-up of new companies (eg, Telavant, Pulmovant, Kinevant) and support established vants as needed (eg, Immunovant, Priovant) in a therapeutic area- and modality-agnostic portfolio.Previously, Senior Vice President of Research and Development Sciences with portfolio oversight of discovery research and development functions including preclinical development, biometrics, clinical pharmacology, and translational sciences. Primary contributor in the approvals of Tepezza for thyroid eye disease and Krystexxa (with methotrexate) for gout. Responsible for scientific diligence for business development evaluations resulting in in-licensing of LPAR-antagonist from Curzion and acquisition of Viela Bio. Site head for South San Francisco, CA. Prior to that, Senior Project Leader at Abbvie with enterprise leadership for clinical development of immunology programs for rheumatology, gastrointerstinal, and dermatology indications. Additionally, Clinical Co-chair for Early Development Immunology Biomarker Forum which provided scientific and translational guidance/gap analysis and strategic direction to discovery programs in immunology. Before Abbvie, Head of Clinical Pharmacology at Gilead Sciences with global responsibilities for clinical development (IND through approval, and post-approval activities) in all therapeutic areas (Oncology, autoimmune disease, Respiratory, Cardiovascular, Fibrosis, and Antivirals including HIV, HBV, HCV). Primary contributor/oversight in the approval of ~10 drugs in HIV, oncology and HCV. Extensive experience in clinical and regulatory strategy aspects of drug development.~150 presentations/publications/talks). Highly experienced in face-to-face and written/teleconference interactions with US FDA, EMA, PMDA (Japan) etc.